Aldeyra Therapeutics (ALDX) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fractyl Health (GUTS) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 74.8% versus a loss of 83.1%. Fractyl Health is the larger company by market cap ($59.3 million vs $58.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | GUTS |
|---|---|---|
| Share price | $0.964 | $4.47 |
| Market cap | $58.15M | $59.29M |
| 1-day change | +1.72% | +5.67% |
| YTD return | -81.70% | -83.98% |
| 1-year return | -83.14% | -74.82% |
| 5-year return | -88.64% | — |
| EPS (TTM) | $-0.38 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $29.34 |
| 52-week low | $0.862 | $4.14 |
| Distance from 52-week high | -83.74% | -84.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +584.65% | +1251.23% |
| Average volume | 1.18M | 156.16K |
| Shares outstanding | 60.33M | 13.26M |
| Employees | 6 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
ALDX vs GUTS FAQ
Which is bigger, Aldeyra Therapeutics or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $59.29M compared with $58.15M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or GUTS?
GUTS returned -74.82% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Fractyl Health in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aldeyra Therapeutics and Medical/Dental Instruments for Fractyl Health.